Loading patent…
AssigneeVAXum, LLC
InventorsAlbert B. Deisseroth, Lixin Zhang
Estimating the term…
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
A method of generating an immune response in an individual with cancer against cells expressing a tumor antigen, comprising administering an effective amount of an adenoviral expression vector, said vector comprising a transcription unit encoding a polypeptide, said polypeptide comprising from the amino terminus a secretory signal sequence, a tumor antigen, and a CD40 ligand wherein said tumor antigen is different from said CD40 ligand and wherein said CD40 ligand is missing all or substantially all of the transmembrane domain rendering the CD40 ligand secretable, and wherein said polypeptide is adapted to elicit Class I restricted cellular immunity, and whereby the generation of said immune response is achieved by injection of the vector directly into tumor nodules of the individual, expressing the tumor antigen.
A method of generating an immune response in an individual with cancer against cells expressing a tumor antigen, comprising administering an effective amount of an adenoviral expression vector, said vector comprising a transcription unit encoding a polypeptide, said polypeptide comprising from the amino terminus a secretory signal sequence, a tumor antigen, and a CD40 ligand wherein said tumor antigen is different from said CD40 ligand and wherein said CD40 ligand is missing all or substantially all of the transmembrane domain rendering the CD40 ligand secretable, and wherein said polypeptide is adapted to elicit Class I restricted cellular immunity, and whereby the generation of said immune response is achieved by injection of the individual's dendritic cells infected with the vector directly into tumor nodules of the individual, expressing the tumor antigen.
Dependencies are inferred from the claim text.